Abstract
We conclude that patients with myocardial infarction from areas endemic for streptococcal infection have high levels of preexisting ASK antibodies. However, these antibodies do not appear to interfere with the efficacy of reperfusion with streptokinase. Similarly, high basal ASK antibody titers do not increase the risk of allergic reactions to streptokinase.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 187-189 |
| Number of pages | 3 |
| Journal | The American Journal of Cardiology |
| Volume | 74 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jul 15 1994 |
Bibliographical note
Funding Information:From the Department of Forensic Medicine, University of Uppsala, Uppsala, Sweden, and the Department of Medicine, University of Florida College of Medicine, Gainesville, Florida. This study was supported by grants from the Swedish Medical Research Council, Stockholm, Sweden, and the American Heart Association, Florida Affiliate, St. Petersburg, Florida. Manuscript received September 10, 1993; revised manuscript received and accepted January 3, 1994.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Antistreptokinase antibodies before and after streptokinase therapy in patients with acute myocardial infarction from areas endemic for streptococcal infection and influence on reperfusion rates'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS